Wedbush Has Pessimistic Outlook of argenx FY2026 Earnings

argenx SE (NASDAQ:ARGX) – Stock analysts at Wedbush reduced their FY2026 EPS estimates for shares of argenx in a research note issued on Wednesday, November 20th. Wedbush analyst D. Nierengarten now expects that the company will earn $21.65 per share for the year, down from their previous forecast of $22.14. Wedbush has a “Outperform” rating and a $560.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is $2.20 per share. Wedbush also issued estimates for argenx’s FY2027 earnings at $34.77 EPS.

Several other equities analysts have also recently issued reports on ARGX. Deutsche Bank Aktiengesellschaft cut argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and set a $617.00 price target on shares of argenx in a research note on Wednesday. Baird R W cut shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Raymond James reaffirmed a “strong-buy” rating and set a $605.00 target price on shares of argenx in a report on Thursday, October 10th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $630.42.

argenx Stock Performance

NASDAQ ARGX opened at $605.92 on Friday. The stock has a market capitalization of $36.23 billion, a P/E ratio of -693.08 and a beta of 0.61. argenx has a 52 week low of $327.73 and a 52 week high of $611.22. The stock has a fifty day moving average of $556.37 and a 200-day moving average of $486.73.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same quarter last year, the business posted ($1.25) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Fiera Capital Corp raised its holdings in shares of argenx by 2.2% during the second quarter. Fiera Capital Corp now owns 165,595 shares of the company’s stock worth $71,212,000 after acquiring an additional 3,506 shares during the period. Cetera Advisors LLC bought a new position in argenx during the 1st quarter worth about $419,000. Simplify Asset Management Inc. raised its stake in shares of argenx by 64.0% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock valued at $1,311,000 after purchasing an additional 944 shares during the period. Perpetual Ltd bought a new stake in shares of argenx in the third quarter valued at about $76,314,000. Finally, Varma Mutual Pension Insurance Co boosted its position in shares of argenx by 20.0% during the second quarter. Varma Mutual Pension Insurance Co now owns 6,000 shares of the company’s stock worth $2,580,000 after buying an additional 1,000 shares during the period. Institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.